儿科患者的阿利洛库马布与异构性家族高胆固醇血症:一个随机临床试验
Raul D Santos1, Albert Wiegman2, Sonia Caprio3
1Lipid Clinic Heart Institute, University of Sao Paulo Medical School Hospital, Sao Paulo, Brazil.
JAMA pediatrics
|February 5, 2024
概括
阿利罗库马布在儿童患者中显著降低了LDL-C 异位家族高胆固醇血清症 (HeFH) 当添加到他类药物时. 这种降脂疗法在每2周一次和每4周一次的剂量方案中都能耐受和有效.
科学领域:
- 心血管医学 心血管医学
- 儿科内分泌学 儿科内分泌学
- 药理学 药理学是指药理学的学科.
背景情况:
- 许多患有异构性家族性高胆固醇血症 (HeFH) 的儿科患者在单独使用他类药物治疗时无法达到目标低密度脂蛋白胆固醇 (LDL-C) 水平.
- 辅助降脂疗法 (LLT) 通常是必要的,强调需要评估新型治疗方法,如阿利罗马布在这个人群.
研究的目的:
- 评估alirocumab作为辅助LLT在患有HeFH和控制不充分的LDL-C水平的儿科患者 (8-17岁) 的疗效和安全性.
- 为了比较每2周 (Q2W) 和每4周 (Q4W) 服用的阿利罗马布在降低LDL-C的有效性.
主要方法:
- 一个3期,随机,双盲,安慰剂控制的临床试验,涉及治疗他类药物或其他LLTs的HeFH的儿科患者.
- 患者被随机分为2:1接受皮下阿利罗库马布 (按体重剂量,Q2W或Q4W) 或安慰剂24周,根据8周的LDL-C水平进行剂量调整.
- 主要疗效终点是LDL-C从基线到第24周的百分比变化.
主要成果:
- 与安慰剂相比,alirocumab在24周的Q2W和Q4W剂量组中显示出LDL-C的统计显著降低.
- 与基线相比,LDL-C百分比变化的最小平方平均差异为Q2W的-43.3%和Q4W的-33.8% (P < .001两者).
- 观察到其他脂质参数的显著改善,治疗组之间的不良事件发生率相似,Q4W阿利罗马布组中仅有两次因不良事件而停止治疗.
结论:
- 服用Q2W或Q4W的阿利罗库马布是一种有效且耐受良好的治疗方法,用于降低儿科患者的LDL-C,HeFH无法通过他类药物控制.
- 这些发现支持使用alirocumab作为一个有价值的辅助LLT选项对于这个特定的儿科患者群体.
- 开放标签期的其他长期数据与双盲期的结果一致.
相关概念视频
02:41Lethal Alleles
Agouti: A Lethal Allele
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
01:20Inborn Errors of Metabolism
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...